insmed fda - Search News

News

US FDA approves Insmed's drug

US FDA approves Insmed's drug as first treatment for a chronic lung disease

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

CNBC on MSN · 1d

Insmed CEO on what’s next for company after FDA greenlights lung disease drug

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.

BioSpace · 1d

Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the market.

Fierce Pharma2d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

Insmed Gets FDA OK of Brinsupri in Non-Cystic Fibrosis Bronchiectasis

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

US FDA approves Insmed's drug

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

Insmed Gets FDA OK of Brinsupri in Non-Cystic Fibrosis Bronchiectasis

Trending now